Cargando…
Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
1998
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150169/ https://www.ncbi.nlm.nih.gov/pubmed/9579835 |
| _version_ | 1782144588671090688 |
|---|---|
| author | de Takats, P. G. Williams, M. V. Hawkins, R. |
| author_facet | de Takats, P. G. Williams, M. V. Hawkins, R. |
| author_sort | de Takats, P. G. |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2150169 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 1998 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-21501692009-09-10 Adjuvant therapy for melanoma: How should we respond to high-dose interferon? de Takats, P. G. Williams, M. V. Hawkins, R. Br J Cancer Research Article Nature Publishing Group 1998-04 /pmc/articles/PMC2150169/ /pubmed/9579835 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Research Article de Takats, P. G. Williams, M. V. Hawkins, R. Adjuvant therapy for melanoma: How should we respond to high-dose interferon? |
| title | Adjuvant therapy for melanoma: How should we respond to high-dose interferon? |
| title_full | Adjuvant therapy for melanoma: How should we respond to high-dose interferon? |
| title_fullStr | Adjuvant therapy for melanoma: How should we respond to high-dose interferon? |
| title_full_unstemmed | Adjuvant therapy for melanoma: How should we respond to high-dose interferon? |
| title_short | Adjuvant therapy for melanoma: How should we respond to high-dose interferon? |
| title_sort | adjuvant therapy for melanoma: how should we respond to high-dose interferon? |
| topic | Research Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150169/ https://www.ncbi.nlm.nih.gov/pubmed/9579835 |
| work_keys_str_mv | AT detakatspg adjuvanttherapyformelanomahowshouldwerespondtohighdoseinterferon AT williamsmv adjuvanttherapyformelanomahowshouldwerespondtohighdoseinterferon AT hawkinsr adjuvanttherapyformelanomahowshouldwerespondtohighdoseinterferon |